Research output per year
Research output per year
Personal profile
Biography
Dr. Cruickshank graduated with a Ph.D. in Molecular Biology and Biochemistry from the University of Western Australia in September 2007. He undertook postdoctoral training at the Murdoch Children’s Research Institute (MCRI) in 2011 where he developed methods for generating and analysing high-throughput DNA methylation from archived biospecimens applied to multiple human birth cohorts. This work generated foundational data on DNA methylation dynamics in humans establishing the rapid rate of changes that occur during early life. He subsequently was appointed to a senior leadership position at Telethon Kids Institute (TKI) in 2012 re-focusing his research on high-risk leukaemia and cancer immunotherapy. This work involved the generation and characterisation of in vitro cellular and animal models for advancing precision medicine and immunotherapy for childhood cancer and leukaemia. Currently, Dr. Cruickshank’s work revolves around deciphering disease mechanisms and innovative therapies for incurable cancers and immune disorders. He was appointed Senior Lecturer Genetics in the School of Biomedical Sciences at The University of Western Australia in 2020 establishing a research and teaching program focused on genetics and genomics of cancer and complex disease.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Industry keywords
- Bioinformatics
- Drug Discovery
- Biotechnology
Research expertise keywords
- Genetics
- Molecular and cellular biology
- Drug development
- Cancer
- leukaemia
- Complex disease, genetics of
Fingerprint
Dive into the research topics where Mark Cruickshank is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy
Cheung, L. C., Aya-Bonilla, C., Cruickshank, M. N., Chiu, S. K., Kuek, V., Anderson, D., Chua, G-A., Singh, S., Oommen, J., Ferrari, E., Hughes, A. M., Ford, J., Kunold, E., Hesselman, M. C., Post, F., Faulk, K. E., Breese, E. H., Guest, E. M., Brown, P. A., Loh, M. L., & 5 others, Jan 2023, In: Leukemia. 37, 1, p. 61-71 11 p.Research output: Contribution to journal › Article › peer-review
Open Access18 Citations (Scopus) -
Single cell transcriptomics reveals cell type specific features of developmentally regulated responses to lipopolysaccharide between birth and 5 years
Read, J. F., Serralha, M., Armitage, J. D., Iqbal, M. M., Cruickshank, M. N., Saxena, A., Strickland, D. H., Waithman, J., Holt, P. G. & Bosco, A., 2023, In: Frontiers in Immunology. 14, 1275937.Research output: Contribution to journal › Article › peer-review
Open Access -
Lipopolysaccharide-induced interferon response networks at birth are predictive of severe viral lower respiratory infections in the first year of life
Read, J. F., Serralha, M., Mok, D., Holt, BJ., Cruickshank, M., Karpievitch, Y. V., Broadhurst, D. I., Sly, P. D., Strickland, D. H., Reinke, S. N., Holt, P. G. & Bosco, A., 5 Aug 2022, In: Frontiers in Immunology. 13, 876654.Research output: Contribution to journal › Article › peer-review
Open Access3 Citations (Scopus) -
Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia
Isobe, T., Takagi, M., Sato-Otsubo, A., Nishimura, A., Nagae, G., Yamagishi, C., Tamura, M., Tanaka, Y., Asada, S., Takeda, R., Tsuchiya, A., Wang, X., Yoshida, K., Nannya, Y., Ueno, H., Akazawa, R., Kato, I., Mikami, T., Watanabe, K., Sekiguchi, M., & 37 others, Dec 2022, In: Nature Communications. 13, 1, 4501.Research output: Contribution to journal › Article › peer-review
Open Access12 Citations (Scopus) -
IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies
Audsley, K. M., Wagner, T., Ta, C., Newnes, H. V., Buzzai, A. C., Barnes, S. A., Wylie, B., Armitage, J., Kaisho, T., Bosco, A., McDonnell, A., Cruickshank, M., Fear, V. S., Foley, B. & Waithman, J., 6 Sept 2021, In: Frontiers in Immunology. 12, 735133.Research output: Contribution to journal › Article › peer-review
Open Access11 Citations (Scopus)
-
Redox imbalance as a driver and therapeutic target for acute lymphoblastic leukaemia
Kenny, J., Sayin, V., Waithman, J., Lister, R., Pflueger, C. & Cruickshank, M.
Department of Health (Western Australia)
1/01/23 → 1/01/26
Project: Research
-
Dissecting gene interactions modulating cancer progression
Cruickshank, M., Pflueger, C., Jones, L., Joo, E., Novakovic, B. & Kaur, P.
1/01/19 → 23/12/22
Project: Research
-
Identification of Factors Regulating Notch-induced CR2 Gene Expression in B Cells
The University of Western Australia
31/12/08 → 31/12/09
Project: Research